InterMune Inc. (ITMN)

ITMN (NASDAQ:Drugs)
$28.29
neg -0.02
-0.07%
Today's Range: 27.25 - 29.38 | ITMN Avg Daily Volume: 3,544,800
Last Update: 04/17/14 - 4:00 PM EDT
Volume: 3,639,254
YTD Performance: 92.06%
Open: $28.37
Previous Close: $28.31
52 Week Range: $8.61 - $38.73
Oustanding Shares: 97,108,400
Market Cap: 2,749,138,804
6-Month Chart
TheStreet Ratings Grade for ITMN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 9 10
Moderate Buy 0 0 0 0
Hold 3 3 2 2
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.75 1.75 1.58 1.54
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -12.42
Price Earnings Comparisons:
ITMN Sector Avg. S&P 500
-12.42 0.00 29.01
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
57.87% 216.09% -44.53%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.10 -0.46 -0.19
Net Income 0.00 0.59 0.00
EPS 0.00 -0.12 0.00
Earnings for ITMN:
EBITDA -0.19B
Revenue 0.03B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $-0.62 $-0.59 $-2.46 $-0.65
Number of Analysts 8 8 10 10
High Estimate $-0.60 $-0.54 $-2.12 $1.53
Low Estimate $-0.65 $-0.68 $-2.76 $-1.66
Prior Year $-0.66 $-0.78 $-2.72 $-2.46
Growth Rate (Year over Year) 5.87% 24.04% 9.60% 73.49%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bearishIntermune downgraded at Credit Suisse

Feb 28, 2014 | 8:09 AM EST

ITMN was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $33 price target. 

bearishIntermune downgraded at Leerink

Feb 26, 2014 | 7:57 AM EST

ITMN was downgraded from Outperform to Market Perform, Leerink Swann said. Valuation call, based on a $41 price target. 

By

Bret Jensen

 | Oct 31, 2013 | 11:00 AM EDT

InterMune, Novavax have promising products and acquisition possibilities.

bullishIntermune upgraded at UBS

Jan 16, 2013 | 8:38 AM EST

ITMN was upgraded to Buy from Neutral, UBS said. $15 price target. Short term hurdles removed. 

bearishIntermune numbers cut at UBS

Aug 15, 2012 | 8:13 AM EDT

Shares of ITMN now seen reaching $8.50, UBS said. Estimates also lowered to reflect Esbriet pricing and sales. Neutral rating.

There were nice reversal-type candles on the weekly charts of the major indices. The DOW a...
A number of stocks on my watch lists are attempting to form positive candles a key suppor...
While last week was a day to pull the plug and contemplate where the market was headed, I ...
Shares of TSLA have formed multiple hammer candles at a key level of support defined by: t...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.